The Administration's Focus on Direct-to-Consumer Prescription Drug Advertising

Trends in False Advertising and Related Competitor Disputes Involving FDA-Regulated Products

Clinical Trial Diversity in Focus

The Demise of Chevron and Implications for Future APA Challenges

How Drug and Device Companies Can Tackle Internet Misinformation

FDA Regulatory & Enforcement Risks Relevant to Academic Medical Centers, Health Systems and Research Institutions

Preview of the Second Annual Ropes & Gray Rare Disease Forum

U.S. Life Sciences Regulatory and Compliance Outlook 2024 (Part IV): Digital Health

U.S. Life Sciences Regulatory and Compliance Outlook 2024 (Part III): Advertising and Promotion

U.S. Life Sciences Outlook 2024 (Part II): Product Development and Pricing

U.S. Life Sciences Regulatory and Compliance Outlook 2024 (Part I): FDA Enforcement and Litigation

FDA’s Draft Guidance on Communication of Scientific Information on Unapproved Uses of Medical Products

FDA’s Proposed Rule on Laboratory Developed Tests

Introducing the U.S. Medical Device Recalls Resource Manual

Recent Developments in Oncology Drug Development

The Regulatory Landscape for Drug Compounding—10 Years After the NECC Outbreak

Key Takeaways from FDA’s Final Guidance on Clinical Decision Support Software

Continued Global Pressure on Drug Pricing & Reimbursement and the Next Frontiers for Effective Market Access

A Recall Readiness Rundown and Recent FDA Actions

Real-World Evidence in Drug Development